Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset.
Guillain-Barré syndrome
Methylprednisolone
Pembrolizumab
Peripheral neuropathy
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
10
09
2020
accepted:
10
09
2020
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
11
2
2021
Statut:
epublish
Résumé
An 85-year-old female was admitted to our hospital for left ureteral cancer and para-aortic lymph node metastasis. To control hematuria, a laparoscopic retroperitoneal nephroureterectomy was performed, and papillary urothelial carcinoma (pT3b) was found. To treat para-aortic lymph node metastasis, she received chemotherapy with gemcitabine and nedaplatin. After 2 cycles, a computed tomography scan revealed its disappearance; however, bilateral lung metastases appeared. The patient was administered second-line therapy with pembrolizumab every 3 weeks. After 3 courses, lung metastases disappeared and she achieved a complete response. After the fifth administration of pembrolizumab, she was readmitted with right upper limb pain and weakness in both lower extremities. She was diagnosed with pembrolizumab-induced grade 3 peripheral neuropathy with Guillain-Barré syndrome-like onset. High-dose monocorticotherapy was initiated for treatment. Three weeks later, the pain and weakness of the limbs improved. After discharge, the dose of prednisolone was tapered and there was no relapse of adverse events. Pembrolizumab was discontinued at the onset of neuropathy, but she maintained a complete response.
Identifiants
pubmed: 33564288
doi: 10.1159/000511567
pii: cro-0013-1490
pmc: PMC7841730
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1490-1494Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Eur J Cancer. 2019 Mar;109:21-27
pubmed: 30682533
JAMA Dermatol. 2015 Nov;151(11):1206-1212
pubmed: 26222619
Drugs Today (Barc). 2015 Jan;51(1):7-20
pubmed: 25685857
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Ann Oncol. 2011 Apr;22(4):991-993
pubmed: 21357649
Curr Neurol Neurosci Rep. 2018 Aug 4;18(10):63
pubmed: 30078154
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Cochrane Database Syst Rev. 2016 Oct 24;10:CD001446
pubmed: 27775812
JAMA Neurol. 2017 Oct 1;74(10):1216-1222
pubmed: 28873125
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Lancet. 2005 Nov 5;366(9497):1653-66
pubmed: 16271648